Active Pharmaceutical Ingredients Market to be Worth $353.0 Billion by 2030: Grand View Research, Inc.

07 Jun 2022
www.prnewswire.com
AntibodyGeneric DrugVaccineAcquisition
SAN FRANCISCO, June 7, 2022 /PRNewswire/ --
The global active pharmaceutical ingredients market size is expected to reach USD 353.0 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by the growth of the biopharmaceutical sector, advancements in active pharmaceutical Ingredients (API) manufacturing, and an increase in the geriatric population.
Key Industry Insights & Findings from the report:
The innovative APIs segment dominated the market in terms of the revenue share of 66.3% in 2021, owing to increasing research and development activities for novel drug development and positive government initiatives.
The cardiovascular disease segment held the largest revenue share of 19.5% in 2021, attributed to the rising prevalence of target disease globally.
The synthetic API segment dominated the market with the largest revenue share of 72.6% in 2021, owing to the higher availability of raw materials and easier protocols for the synthesis of these molecules.
North America accounted for the largest revenue share of 39.0% in 2021 and is expected to maintain its lead over the forecast period. This is attributed to the rising epidemiology of cancer, along with other lifestyle-induced diseases, thus encouraging the R&D activities, thereby boosting the market growth.
Get more Latest Industry Insights from 191-page market research report, "Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Type Of Synthesis (Biotech, Synthetic), By Type Of Manufacturer (Captive, Merchant), By Type, By Application, By Region, And Segment Forecasts, 2022 - 2030", published by Grand View Research.
Active Pharmaceutical Ingredients Market Growth & Trends
The growth of the captive API segment is propelled by companies investing in solving challenges and developing new chemical ways for the production of APIs in-house. This aids in reducing costs and the risk of contamination. Artificial intelligence and protein synthesis are expected to facilitate faster development with greater control over the process.
The rising prevalence of chronic and lifestyle-based conditions, such as cardiovascular diseases, is accelerating the demand for API. For instance, as per U.S. Pharmacist in 2020, 47% of adults have at least one risk factor that supports cardiovascular disease development. Cardiovascular diseases are one of the global, critical public health burdens driving extensive R&D for APIs in the field.
The active pharmaceutical Ingredients market was positively influenced by the COVID-19 pandemic, as countries and significant players produce large quantities of components to meet the demand for the treatment of COVID-19.  As a result of the outbreak, drug companies have changed the companies' strategies to focus on a larger patient population. To treat coronavirus, the U.S., for example, requested that HCQ be imported from India. The virus has also impacted Canada's medicine supply system, potentially causing complications for patients. The increasing importance of generics, rise in consumption of biopharmaceuticals, and expanding drug research and development activities for drug manufacturing are the primary drivers driving the growth of the market. However, the market's expansion is likely to be hampered by unfavourable drug price control regimes in several countries and high manufacturing costs.
Developing nations like India are receiving an increased preference in the market over dominant API market countries, like China, owing to geopolitical situations. Furthermore, India has quality raw materials and products, a large workforce, a vast distribution network, and government subsidies through the "Make in India" program.
To address unmet medical needs, companies are collaborating to develop novel treatments. This allows firms to use their resources to aid in the development of products and enhance the supply chain. In November 2021, Merck & Co Inc. announced that it has acquired Acceleron Pharma, this acquisition would help Merck & Co to expand their cardiovascular portfolio and pipeline.
Active Pharmaceutical Ingredients Market
Segmentation
Grand View Research has segmented the global active pharmaceutical Ingredients market based on the type of synthesis, type of manufacturer, type, application, and region:
Active Pharmaceutical Ingredients Market - Type of Synthesis Outlook (Revenue, USD Billion, 2018 - 2030)
Biotech
Monoclonal Antibodies
Vaccines
Synthetic
Active Pharmaceutical Ingredients Market - Type of Manufacturer Outlook (Revenue, USD Billion, 2018 - 2030)
Captive APIs
Merchant APIs
Active Pharmaceutical Ingredients Market - Type Outlook (Revenue, USD Billion, 2018 - 2030)
Generic APIs
Active Pharmaceutical Ingredients Market - Application Outlook (Revenue, USD Billion, 2018 - 2030)
Oncology
CNS and Neurology
Orthopedic
Endocrinology
Pulmonology
Nephrology
Ophthalmology
Others
Active Pharmaceutical Ingredients Market - Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Russia
Japan
China
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
UAE
Saudi Arabia
List of Key Players in the Active Pharmaceutical Ingredients Market
Merck & Co., Inc.
Check out more related studies published by Grand View Research:
- The global cannabis pharmaceuticals market size is expected to reach USD 127.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 104.2% from 2022 to 2028. Rapid growth in applications of cannabis for various indications including pain, inflammation, sleep disorders, anorexia, epilepsy, schizophrenia, and multiple sclerosis is estimated to drive market growth. There is a shift from cannabis herbal preparations to prescription drugs. Demand for processed, quantified, and packaged cannabis products is significantly increasing. Moreover, consumer, as well as regulatory acceptance of cannabis products, is increasing which in turn is positively impacting market growth.
Europe Pharmaceutical Market - The Europe pharmaceutical market size is expected to reach USD 432.12 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 5.4% from 2021 to 2028. The market is driven by an increasing prevalence of diseases, a growing elderly population, and the approval and launch of novel products in the European region.
High Potency Active Pharmaceutical Ingredients Market - The global high potency active pharmaceutical ingredients market size is expected to reach USD 38.84 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.4% from 2021 to 2028. The market is driven by an increased focus on targeted therapies and a surge in demand for cancer therapies.
Browse through Grand View Research's Pharmaceuticals Industry Research Reports.
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Grand View Compass | Grand View Pipeline
Follow Us: LinkedIn | Twitter
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.